We recently compiled a list of the 11 Most Undervalued Pharma Stocks to Invest In. Pfizer Inc. (NYSE:PFE) is one of the most undervalued stocks on this list.
TheFly reported on May 27 that PFE and Innovent Biologics announced a global strategic licensing and collaboration agreement covering the research and development of 12 early-stage oncology programs, including antibody-drug conjugates and multi-specific antibody therapies. The alliance combines PFE’s global development and commercialization infrastructure with Innovent’s oncology discovery and early clinical expertise. The portfolio includes eight Innovent-originated and four Pfizer-originated programs, with select assets to be jointly developed and funded. Under the structure, Innovent will advance programs through Phase 1 before PFE assumes leadership for later-stage global development. Financial terms include a $650 million upfront payment to Innovent and potential milestone payments of up to $9.85 billion, plus tiered royalties and shared commercialization rights in key regions.
Separately, on May 20, Pfizer Inc. (NYSE:PFE) reported Phase 2 clinical data for its investigational 25-valent pneumococcal conjugate vaccine PF-07872412, evaluating safety, tolerability, and immune response in infants versus PREVNAR 20. The regimen followed a four-dose schedule at 2, 4, 6, and 12–15 months of age. Results showed strong immunogenic responses across all 25 serotypes, with notably higher antibody titers for key strains such as serotype 3 compared with the comparator vaccine. Safety outcomes were consistent with established pneumococcal vaccines, with similar local injection-site reactions and no new safety concerns. Based on these findings, PFE initiated a pivotal Phase 3 pediatric program in May 2026 to further evaluate efficacy and immunogenicity across a larger population.
Pfizer Inc. (NYSE:PFE) is a global biopharmaceutical company that develops medicines and vaccines. It focuses on key areas including oncology, immunology, internal medicine, and infectious diseases.
While we acknowledge the risk and potential of PFE as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than PFE and that has 10,000% upside potential, check out our report about this cheapest AI stock.
READ NEXT: 12 Best Strong Buy Tech Stocks to Invest In Now and 10 Most Widely Held Stocks by Individuals in 2026 .
Disclosure: None. Follow Insider Monkey on Google News.
